A novel reverse perilesional home phototherapy can promote the repigmentation of vitiligo patches with complete leukotrichia: A 12‐week, open‐label, double‐arm, multicenter, randomized clinical trial
Photodermatology, Photoimmunology & Photomedicine · 2024
DOI: 10.1111/phpp.12974 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Photodermatology, Photoimmunology & Photomedicine, 2024. Verfasst von Na Lei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Vitiligo, Ultraviolet Therapy. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/Purpose Existing phototherapies are ineffective for treating patients with vitiligo with complete leukotrichia. We compared the efficacy of reverse perilesional irradiation, during which only the lesional areas are covered, with conventional narrowband ultraviolet B (NB‐UVB) home phototherapy for repigmentation of non‐segmental vitiligo in patients with complete leukotrichia.
Methods
This was a 12‐week, open‐label, double‐arm, multicenter clinical trial, with a total of 121 patients with non‐segmental vitiligo who were randomly divided into two groups (both received topical tacrolimus): the conventional NB‐UVB irradiation (CI) and reverse perilesional NB‐UVB irradiation (RI) groups.
Results
A statistically significant difference in improvement from baseline was observed in the RI group compared with the findings in the CI group (−30.8% ± 11.8% vs. −25.5% ± 11.05%, respectively [ p = .010]; pair‐wise comparison p = .900 at week 4, p = .104 at week 8, and p = .010 at week 12). At week 12, the average percentage change from baseline of leukotrichia in the irradiation area significantly decreased from 100% to 82.2% ± 13.65% in the RI group, and from 100% to 88.7% ± 9.64% in the CI group ( p = .027). Adverse events were minor, including desquamation, dryness, erythema, and blisters. No severe or lasting side effects were observed during the study.
Conclusion
RI mediated better repigmentation of vitiligo with complete leukotrichia than CI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Dermatology, Shandong Provincial Hospital for Skin Diseases and Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jina…
- Department of Dermatology, Taicang Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Suzhou, China.
- Department of Dermatology, Changshu Second People's Hospital, Suzhou, China.
- Department of Dermatology, Jiangyan Dermatology Hospital, Taizhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lei, N., Cao, X., Feng, Y., Liu, G., Feng, J., Zhao, Y., Zhao, Z., Li, Z., Song, L., & Lu, Y. (2024). A novel reverse perilesional home phototherapy can promote the repigmentation of vitiligo patches with complete leukotrichia: A 12‐week, open‐label, double‐arm, multicenter, randomized clinical trial. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.12974
Vancouver
Lei N, Cao X, Feng Y, Liu G, Feng J, Zhao Y, et al. A novel reverse perilesional home phototherapy can promote the repigmentation of vitiligo patches with complete leukotrichia: A 12‐week, open‐label, double‐arm, multicenter, randomized clinical trial. Photodermatology, Photoimmunology & Photomedicine. 2024. doi:10.1111/phpp.12974
BibTeX
@article{Lei2024,
author = {Lei, Na and Cao, Xuechen and Feng, Yifei and Liu, Guoyan and Feng, Jianqing and Zhao, Yidong and Zhao, Zhiming and Li, Ziyu and Song, Lebin and Lu, Yan},
title = {A novel reverse perilesional home phototherapy can promote the repigmentation of vitiligo patches with complete leukotrichia: A 12‐week, open‐label, double‐arm, multicenter, randomized clinical trial},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2024},
doi = {10.1111/phpp.12974}
}
EUVIMED